Mn Services Vermogensbeheer B.V. increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,963 shares of the pharmaceutical company’s stock after purchasing an additional 600 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Vertex Pharmaceuticals were worth $8,087,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently modified their holdings of VRTX. Oregon Public Employees Retirement Fund grew its holdings in Vertex Pharmaceuticals by 16,530.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock valued at $28,000 after buying an additional 4,583,156 shares in the last quarter. FMR LLC grew its holdings in Vertex Pharmaceuticals by 13.3% in the 4th quarter. FMR LLC now owns 20,483,109 shares of the pharmaceutical company’s stock valued at $3,394,256,000 after buying an additional 2,411,631 shares in the last quarter. Norges Bank purchased a new stake in Vertex Pharmaceuticals in the 4th quarter valued at $380,584,000. Jennison Associates LLC grew its holdings in Vertex Pharmaceuticals by 11.9% in the 4th quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock valued at $1,150,296,000 after buying an additional 739,128 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in Vertex Pharmaceuticals by 74.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 601,559 shares of the pharmaceutical company’s stock valued at $99,685,000 after buying an additional 257,683 shares in the last quarter. Hedge funds and other institutional investors own 94.92% of the company’s stock.
A number of equities analysts have recently weighed in on the company. BidaskClub upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 16th. Cowen reaffirmed a “buy” rating and issued a $220.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 6th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $209.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, May 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, May 1st. Finally, ValuEngine raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $203.35.
NASDAQ:VRTX opened at $166.72 on Thursday. The company has a market cap of $42.74 billion, a P/E ratio of 58.91, a PEG ratio of 2.39 and a beta of 1.56. The company has a current ratio of 3.78, a quick ratio of 3.66 and a debt-to-equity ratio of 0.13. Vertex Pharmaceuticals Incorporated has a 52-week low of $144.07 and a 52-week high of $195.81.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.49. The firm had revenue of $857.00 million for the quarter, compared to the consensus estimate of $853.00 million. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The firm’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.76 EPS. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 3.06 EPS for the current fiscal year.
In related news, EVP Michael Parini sold 1,622 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $172.06, for a total transaction of $279,081.32. Following the transaction, the executive vice president now owns 37,332 shares in the company, valued at approximately $6,423,343.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey M. Leiden sold 33,058 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $175.01, for a total value of $5,785,480.58. Following the transaction, the chief executive officer now owns 136,953 shares in the company, valued at approximately $23,968,144.53. The disclosure for this sale can be found here. Insiders have sold a total of 81,705 shares of company stock worth $14,703,196 in the last 90 days. 0.70% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Mn Services Vermogensbeheer B.V. Raises Position in Vertex Pharmaceuticals Incorporated (VRTX)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2019/05/16/mn-services-vermogensbeheer-b-v-raises-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Read More: What is a Buy-Side Analyst?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.